Article Information
History
- February 9, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- David Cheishvili1,2,
- Chifat Wong1,
- Mohammad Mahbubul Karim3,
- Mohammad Golam Kibria3,
- Nusrat Jahan3,
- Pappu Chandra Das3,
- Md. Abul Khair Yousuf4,
- Md. Atikul Islam4,
- Dulal Chandra Das4,
- Sheikh Mohammad Noor-E-Alam4,
- Moshe Szyf5,*,
- Wasif A. Khan3 and
- Mammun-Al-Mahtab4
- 1HKG Epitherapeutics Ltd., Unit 613 Biotech Center 2, Science Park, Shatin, Hong Kong, SAR, China
- 2Gerald Bronfman Department of Oncology, McGill University Montreal, Canada
- 3International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b) Dhaka, Bangladesh
- 4Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh
- 5Department of Pharmacology and Therapeutics, McGill University, Montreal Canada
- ↵*To whom correspondence should be addressed at: Moshe Szyf, Department of Pharmacology and Therapeutics, McGill University, 3655 Sir Walter Scott Promenade, Montreal, Quebec Canada H3G 1Y6, moshe.szyf{at}mcgill.ca
Posted February 09, 2021.
epiLiver a novel tumor specific, high throughput and cost-effective blood test for specific detection of liver cancer (HCC)
